SSSachin Shah

Sachin Shah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sachin Shah has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Arne Ohlsson

    University of Toronto, Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation, Toronto, Canada

    5 shared publications
  • Vibhuti S Shah

    University of Toronto Department of Paediatrics and Institute of Health Policy, Management and Evaluation 600 University Avenue Toronto Canada M5G 1X5

    3 shared publications
  • Amita Kaul

    1 shared publication
  • Amita Kaul

    Department of Neonatal and Pediatric Intensive Care Services, Surya Mother and Child superspecialty Hospital, Pune, India

    1 shared publication
  • Henry L Halliday

    Retired Honorary Professor of Child Health, Queen's University 74 Deramore Park South Belfast UK BT9 5JY

    1 shared publication
  • Henry L. Halliday

    Royal Maternity Hospital

    1 shared publication

Latest Publications

  • Open Access

    Clinical experience of use of percutaneous peripheral arterial cannulation in sick neonates in a developing country

    by Sachin Shah, Amita Kaul, Shambhavi Mishra, Shridhar Pawale

    Background: Continuous invasive arterial monitoring is necessary in sick neonates needing hemodynamic and ventilatory support. The primary objective of our study was to describe clinical experience with percutaneous peripheral arterial cannulation (PAC) in sick neonates. Methods: Neonates needing PAC were prospectively enrolled in the study. Inclusion criteria were: neonates needing respiratory support (invasive or non-invasive), neonates requiring vasoactive medications or neonate likely to need more than 5 sampling pricks in 24 h. Results: One hundred eight neonates (93.1%) needed cannulation of one arterial site while 8 (6.9%) needed cannulation of 2 arterial sites, thus giving a total of 124 cannulations. Out of the 124 cannulations, 102 (82%) were performed in first attempt, while 22 (18%) cannulations needed 2 or more attempts. Serious complications like discolouration of digits, blanching of skin or bleeding were seen in 6 (4.9%) cannulations. These resolved after removal of arterial line and no long term consequences were noted. On comparing neonates having radial arterial cannulation(n = 108) with posterior tibial arterial cannulation (n = 16) there was no difference in duration of arterial line between radial artery group (mean, SD 53.30 ± 22.56) and posterior tibial artery group (mean, SD 48.25 ± 27.39). However, more attempts were needed to cannulate post tibial artery (mean, SD 2.25 ± 1.32) as compared to radial artery (mean 1.22 ± 0.789) and this difference was statistically significant (MD -1.02, 95% CI − 1.75 to − 0.30). There was no difference in incidence of serious complications between the radial artery group (3.7%, n = 4) as compared to posterior tibial group (5.5%, n = 1, OR 0.57, 95% CI 0.06–5.51, p = 0.63). Conclusions: Peripheral arterial cannulation is a safe method for hemodynamic monitoring and blood sampling in sick neonates. Complications can be minimized by diligent monitoring and proactive removal of line if there is damping of tracing.


  • Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants

    by Arne Ohlsson, Rajneesh Walia, Sachin S Shah

    Background Indomethacin is used as standard therapy to close a patent ductus arteriosus (PDA) but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo‐oxygenase inhibitor, may be as effective as indomethacin with fewer adverse effects. Objectives To determine the effectiveness and safety of ibuprofen compared with indomethacin, other cyclo‐oxygenase inhibitor(s), placebo, or no intervention for closing a patent ductus arteriosus in preterm, low‐birth‐weight, or preterm and low‐birth‐weight infants. Search methods We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 10), MEDLINE via PubMed (1966 to 30 November 2017), Embase (1980 to 30 November 2017), and CINAHL (1982 to 30 November 2017). We searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi‐randomised trials. Selection criteria Randomised or quasi‐randomised controlled trials of ibuprofen for the treatment of a PDA in preterm, low birth weight, or both preterm and low‐birth‐weight newborn infants. Data collection and analysis Data collection and analysis conformed to the methods of the Cochrane Neonatal Review Group. We used the GRADE approach to assess the quality of evidence. Main results We included 39 studies enrolling 2843 infants. Ibuprofen (IV) versus placebo: IV Ibuprofen (3 doses) reduced the failure to close a PDA compared with placebo (typical relative risk (RR); 0.62 (95% CI 0.44 to 0.86); typical risk difference (RD); ‐0.18 (95% CI ‐0.30 to ‐0.06); NNTB 6 (95% CI 3 to 17); I2 = 65% for RR and I2 = 0% for RD; 2 studies, 206 infants; moderate‐quality the evidence). One study reported decreased failure to close a PDA after single or three doses of oral ibuprofen compared with placebo (64 infants; RR 0.26, 95% CI 0.11 to 0.62; RD ‐0.44, 95% CI ‐0.65 to ‐0.23; NNTB 2, 95% CI 2 to 4; I2 test not applicable). Ibuprofen (IV or oral) compared with indomethacin (IV or oral): Twenty‐four studies (1590 infants) comparing ibuprofen (IV or oral) with indomethacin (IV or oral) found no significant differences in failure rates for PDA closure (typical RR 1.07, 95% CI 0.92 to 1.24; typical RD 0.02, 95% CI ‐0.02 to 0.06; I2 = 0% for both RR and RD; moderate‐quality evidence). A reduction in NEC (necrotising enterocolitis) was noted in the ibuprofen (IV or oral) group (18 studies, 1292 infants; typical RR 0.68, 95% CI 0.49 to 0.94; typical RD ‐0.04, 95% CI ‐0.07 to ‐0.01; NNTB 25, 95% CI 14 to 100; I2 = 0% for both RR and RD; moderate‐quality evidence). There was a statistically significant reduction in the proportion of infants with oliguria in the ibuprofen group (6 studies, 576 infants; typical RR 0.28, 95% CI 0.14 to 0.54; typical RD ‐0.09, 95% CI ‐0.14 to ‐0.05; NNTB 11, 95% CI 7 to 20; I2 = 24% for RR and I2 = 69% for RD; moderate‐quality evidence). The serum/plasma creatinine levels 72 hours after initiation of treatment were statistically significantly lower in the ibuprofen group (11 studies, 918 infants; MD ‐8.12 µmol/L, 95% CI ‐10.81 to ‐5.43). For this comparison, there was high between‐study heterogeneity (I2 = 83%) and low‐quality evidence. Ibuprofen (oral) compared with indomethacin (IV or oral): Eight studies (272 infants) reported on failure rates for PDA closure in a subgroup of the above studies comparing oral ibuprofen with indomethacin (IV or oral). There was no significant difference between the groups (typical RR 0.96, 95% CI 0.73 to 1.27; typical RD ‐0.01, 95% CI ‐0.12 to 0.09; I2 = 0% for both RR and RD). The risk of NEC was reduced with oral ibuprofen compared with indomethacin (IV or oral) (7 studies, 249 infants; typical RR 0.41, 95% CI 0.23 to 0.73; typical RD ‐0.13, 95% CI ‐0.22 to ‐0.05; NNTB 8, 95% CI 5 to 20; I2 = 0% for both RR and RD). There was low‐quality evidence for these two outcomes. There was a decreased risk of failure to close a PDA with oral ibuprofen compared with IV ibuprofen (5 studies, 406 infants; typical RR 0.38, 95% CI 0.26 to 0.56; typical RD ‐0.22, 95% CI ‐0.31 to ‐0.14; NNTB 5, 95% CI 3 to 7; moderate‐quality evidence). There was a decreased risk of failure to close a PDA with high‐dose versus standard‐dose of IV ibuprofen (3 studies 190 infants; typical RR 0.37, 95% CI 0.22 to 0.61; typical RD ‐ 0.26, 95% CI ‐0.38 to ‐0.15; NNTB 4, 95% CI 3 to 7); I2 = 4% for RR and 0% for RD); moderate‐quality evidence). Early versus expectant administration of IV ibuprofen, echocardiographically‐guided IV ibuprofen treatment versus standard IV ibuprofen treatment, continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, and rectal ibuprofen versus oral ibuprofen were studied in too few trials to allow for precise estimates of any clinical outcomes. Authors' conclusions Ibuprofen is as effective as indomethacin in closing a PDA. Ibuprofen reduces the risk of NEC and transient renal insufficiency. Therefore, of these two drugs, ibuprofen appears to be the drug of choice. The effectiveness of ibuprofen versus paracetamol is assessed in a separate review. Oro‐gastric administration of ibuprofen appears as effective as IV administration. To make further recommendations, studies are needed to assess the effectiveness of high‐dose versus standard‐dose ibuprofen, early versus expectant administration of ibuprofen, echocardiographically‐guided versus standard IV ibuprofen, and continuous infusion versus intermittent boluses of ibuprofen. Studies are lacking evaluating the effect of ibuprofen on longer‐term outcomes in infants with PDA.


  • Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants

    by Arne Ohlsson, Sachin S Shah

    Background Patent ductus arteriosus (PDA) complicates the clinical course of preterm infants and increases the risk of adverse outcomes. Indomethacin has been the standard treatment to close a PDA but is associated with renal, gastrointestinal, and cerebral side effects. Ibuprofen has less effect on blood flow velocity to important organs. Objectives Primary objectives To determine the effectiveness and safety of ibuprofen compared to placebo/no intervention, or other cyclo‐oxygenase inhibitor drugs in the prevention of PDA in preterm infants. Search methods We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 10), MEDLINE via PubMed (1966 to 17 October 2018), Embase (1980 to 17 October 2018), and CINAHL; 1982 to 17 October 2018). We searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi‐randomised trials. Selection criteria Randomised and quasi‐randomised controlled trials comparing ibuprofen with placebo/no intervention or other cyclo‐oxygenase inhibitor drugs to prevent PDA in preterm or low birth weight infants. Data collection and analysis We extracted outcomes data including presence of PDA on day three or four of life (after 72 hours of treatment), need for surgical ligation or rescue treatment with cyclo‐oxygenase inhibitors, mortality, cerebral, renal, pulmonary, and gastrointestinal complications. We performed meta‐analyses and reported treatment estimates as typical mean difference (MD), risk ratio (RR), risk difference (RD) and, if statistically significant, number needed to treat to benefit (NNTB) or to harm (NNTH), along with their 95% confidence intervals (CI). We assessed between‐study heterogeneity by the I‐squared test (I²). We used the GRADE approach to assess the quality of evidence. Main results In this updated analysis, we included nine trials (N = 1070 infants) comparing prophylactic ibuprofen (IV or oral) with placebo/no intervention or indomethacin. Ibuprofen (IV or oral) probably decreases the risk of PDA on day 3 or 4 (typical RR 0.39, 95% CI 0.31 to 0.48; typical RD ‐0.26, 95% CI ‐0.31 to ‐0.21; NNTB 4, 95% CI 3 to 5; 9 trials; N = 1029) (moderate‐quality evidence). In the control group, the spontaneous closure rate was 58% by day 3 to 4 of age. In addition, ibuprofen probably decreases the need for rescue treatment with cyclo‐oxygenase inhibitors (typical RR 0.17, 95% CI 0.11 to 0.26; typical RD ‐0.27, 95% CI ‐0.32 to ‐0.22; NNTB 4; 95% CI 3 to 5),and the need for surgical ductal ligation (typical RR 0.46, 95% CI 0.22 to 0.96; typical RD ‐0.03, 95% CI ‐0.05 to ‐0.00; NNTB 33, 95% CI 20 to infinity; 7 trials; N = 925) (moderate‐quality evidence). There was a possible decrease in the risk of grade 3 or 4 intraventricular haemorrhage (IVH) in infants receiving prophylactic ibuprofen (typical RR 0.67, 95% CI 0.45 to 1.00; I² = 34%; typical RD ‐0.04, 95% CI ‐0.08 to‐ 0.00; I² = 60%; 7 trials; N = 925) (moderate‐quality evidence). High quality evidence showed increased risk for oliguria (typical RR 1.45, 95% CI 1.04 to 2.02; typical RD 0.06, 95% CI 0.01 to 0.11; NNTH 17, 95% CI 9 to 100; 4 trials; N = 747). Low quality results from four studies (N = 202) showed that administering oral ibuprofen may decrease the risk of PDA (typical RR 0.47, 95% CI 0.30 to 0.74) and may increase risk of gastrointestinal bleeding (NNTH 7, 95% CI 4 to 25). No evidence of a difference was identified for mortality, any intraventricular haemorrhage (IVH), or chronic lung disease. Authors' conclusions This review shows that prophylactic use of ibuprofen, compared to placebo or no intervention, probably decreases the incidence of patent ductus arteriosus, the need for rescue treatment with cyclo‐oxygenase inhibitors, and for surgical ductal closure. Adverse effects associated with ibuprofen (IV or oral) included increased risks for oliguria, increase in serum creatinine levels, and increased risk of gastrointestinal haemorrhage. There was a reduced risk for intraventricular haemorrhage (grade III ‐ IV) but no evidence of a difference in mortality, chronic lung disease, necrotising enterocolitis, or time to reach full feeds. In the control group, the patent ductus arteriosus had closed spontaneously by day 3 or 4 in 58% of neonates. Prophylactic treatment exposes a large proportion of infants unnecessarily to a drug that has important side effects without conferring any important short‐term benefits. Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus. Until long‐term follow‐up results of the trials included in this review have been published, no further trials of prophylactic ibuprofen are recommended. A new approach to patent ductus arteriosus management is an early targeted treatment based on echocardiographic criteria within the first 72 hours of life, that have a high sensitivity for diagnosing a patent ductus arteriosus that is unlikely to close spontaneously. Such trials are currently ongoing in many parts of the world. Results of such trials will be included in updates of our "Ibuprofen for treatment of PDA" review.


  • Biomarkers in sepsis

    by Sachin Shah, Amita Kaul


  • Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates

    by Sachin S Shah, Arne Ohlsson, Henry L Halliday, Vibhuti S Shah

    Bronchopulmonary dysplasia (BPD) remains an important cause of mortality and morbidity in preterm infants and inflammation plays a significant role in its pathogenesis. The use of inhaled corticosteroids may modulate the inflammatory process without concomitant high systemic steroid concentrations and less risk of adverse effects. This is an update of a review published in 2012 (Shah 2012). We recently updated the related review on "Inhaled versus systemic corticosteroids for treating bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates". To determine the effect of inhaled versus systemic corticosteroids started within the first 7 days of life on preventing death or BPD in ventilated very low birth weight infants. We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 1), MEDLINE via PubMed (1966 to 23 February 2017), Embase (1980 to 23 February 2017), and CINAHL (1982 to 23 February 2017). We searched clinical trials registers, conference proceedings and the reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi-randomised trials. Randomised or quasi-randomised controlled trials comparing inhaled versus systemic corticosteroid therapy (irrespective of dose and duration) starting in the first seven days of life in very low birth weight preterm infants receiving assisted ventilation. Clinical outcomes data were extracted and analysed using Review Manager. When appropriate, meta-analysis was performed using typical relative risk (RR), typical risk difference (RD) and weighted mean difference (WMD). Meta-analyses were performed using typical relative risk, typical risk difference (RD), and weighted mean difference with their 95% confidence intervals (CI). If RD was statistically significant, the number needed to benefit or the number needed to harm was calculated. We assessed the quality of evidence was evaluated using GRADE principles. We included two trials that involved 294 infants. No new studies were included for the 2017 update. The incidence of death or BPD at 36 weeks' postmenstrual age was not statistically significantly different between infants who received inhaled or systemic steroids (RR 1.09, 95% CI 0.88 to 1.35; RD 0.05, 95% CI -0.07 to 0.16; 1 trial, N = 278). The incidence of BPD at 36 weeks' postmenstrual age among survivors was not statistically significant between groups (RR 1.34, 95% CI 0.94 to 1.90; RD 0.11, 95% CI -0.02 to 0.24; 1 trial, N = 206). There was no statistically significant difference in the outcomes of BPD at 28 days, death at 28 days or 36 weeks' postmenstrual age and the combined outcome of death or BPD by 28 days between groups (2 trials, N = 294). The duration of mechanical ventilation was significantly longer in the inhaled steroid group compared with the systemic steroid group (typical MD 4 days, 95% CI 0.2 to 8; 2 trials, N = 294; I² = 0%) as was the duration of supplemental oxygen (typical MD 11 days, 95% CI 2 to 20; 2 trials, N = 294; I² = 33%). The incidence of hyperglycaemia was significantly lower with inhaled steroids (RR 0.52, 95% CI 0.39 to 0.71; RD -0.25, 95% CI -0.37 to -0.14; 1 trial, N = 278; NNTB 4, 95% CI 3 to 7 to avoid 1 infant experiencing hyperglycaemia). The rate of patent ductus arteriosus increased in the group receiving inhaled steroids (RR 1.64, 95% CI 1.23 to 2.17; RD 0.21, 95% CI 0.10 to 0.33; 1 trial, N = 278; NNTH 5, 95% CI 3 to 10). In a subset of surviving infants in the United Kingdom and Ireland there were no significant differences in developmental outcomes at 7 years of age. However, there was a reduced risk of having ever been diagnosed as asthmatic by 7 years of age in the inhaled steroid group compared with the systemic steroid group (N = 48) (RR 0.42, 95% CI 0.19 to 0.94; RD -0.31, 95% CI -0.58 to -0.05; NNTB 3, 95% CI 2 to 20). According to GRADE the quality of the evidence was moderate to low. Evidence was downgraded on the basis of design (risk of bias), consistency (heterogeneity) and precision of the estimates. Both studies received grant support and the industry provided aero chambers and metered dose inhalers of budesonide and placebo for the larger study. No conflict of interest was identified. We found no evidence that early inhaled steroids confer important advantages over systemic steroids in the management of ventilator-dependent preterm infants. Based on this review inhaled steroids cannot be recommended over systemic steroids as a part of standard practice for ventilated preterm infants. Because they might have fewer adverse effects than systemic steroids, further randomised controlled trials of inhaled steroids are needed that address risk/benefit ratio of different delivery techniques, dosing schedules and long-term effects, with particular attention to neurodevelopmental outcome.


  • Intraventricular antibiotics for bacterial meningitis in neonates

    by Sachin S Shah, Arne Ohlsson, Vibhuti S Shah

    Neonatal meningitis may be caused by bacteria, especially gram-negative bacteria, which are difficult to eradicate from the cerebrospinal fluid (CSF) using safe doses of antibiotics. In theory, intraventricular administration of antibiotics would produce higher antibiotic concentrations in the CSF than intravenous administration alone, and eliminate the bacteria more quickly. However, ventricular taps may cause harm. To assess the effectiveness and safety of intraventricular antibiotics (with or without intravenous antibiotics) in neonates with meningitis (with or without ventriculitis) as compared to treatment with intravenous antibiotics alone. The Cochrane Library, Issue 2, 2007; MEDLINE; EMBASE; CINAHL and Science Citation Index were searched in June 2007. The Oxford Database of Perinatal Trials was searched in June 2004. Pediatric Research (abstracts of proceedings) were searched (1990 to April 2007) as were reference lists of identified trials and personal files. No language restrictions were applied.This search was updated in May 2011. Selection criteria for study inclusion were: randomised or quasi-randomised controlled trials in which intraventricular antibiotics with or without intravenous antibiotics were compared with intravenous antibiotics alone in neonates (< 28 days old) with meningitis. One of the following outcomes was required to be reported: mortality during initial hospitalisation; neonatal or infant mortality, or both; neurodevelopmental outcome; duration of hospitalisation; duration of culture positivity of CSF and side effects. All review authors abstracted information for outcomes reported and one review author checked for discrepancies and entered data into RevMan 5.1. Risk ratio (RR), risk difference (RD), number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH), and mean difference (MD), using the fixed-effect model are reported with 95% confidence intervals (CI). The updated search in June 2011 did not identify any new trials. One study is included in the review. This study assessed the effect of intraventricular gentamicin in a mixed population of neonates (69%) and older infants (31%) with gram-negative meningitis and ventriculitis. Mortality was statistically significantly higher in the group that received intraventricular gentamicin in addition to intravenous antibiotics compared to the group receiving intravenous antibiotics alone (RR 3.43; 95% CI 1.09 to 10.74; RD 0.30; 95% CI 0.08 to 0.53); NNTH 3; 95% CI 2 to 13). Duration of CSF culture positivity did not differ significantly (MD -1.20 days; 95% CI -2.67 to 0.27). In one trial that enrolled infants with gram-negative meningitis and ventriculitis, the use of intraventricular antibiotics in addition to intravenous antibiotics resulted in a three-fold increased RR for mortality compared to standard treatment with intravenous antibiotics alone. Based on this result, intraventricular antibiotics as tested in this trial should be avoided. Further trials comparing these interventions are not justified in this population.


  • Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates

    by Sachin S Shah, Arne Ohlsson, Henry L Halliday, Vibhuti S Shah

    Chronic lung disease (CLD) remains an important cause of mortality and morbidity in preterm infants and inflammation plays an important role in its pathogenesis. The use of inhaled corticosteroids may modulate the inflammatory process without concomitant high systemic steroid concentrations and less risk of adverse effects. To determine the effect of inhaled versus systemic corticosteroids started within the first two weeks of life on preventing CLD in ventilated very low birth weight (VLBW) infants. Randomised and quasi‐randomised trials were identified by searching The Cochrane Library, MEDLINE , EMBASE , CINAHL, reference lists of published trials and abstracts published in Pediatric Research or electronically on the Pediatric Academic Societies web site in June 2007.This search was updated in June 2011 and included additional searches of Clinicaltrials.gov, Controlled‐trials.com and Web of Science. Randomised or quasi‐randomised clinical trials comparing inhaled versus systemic corticosteroid therapy (regardless of the dose and duration of therapy) started in the first two weeks of life in VLBW infants receiving assisted ventilation. Outcomes including CLD at 28 days or 36 weeks postmenstrual age (PMA), mortality, the combined outcome of death or CLD at 28 days or 36 weeks PMA, other pulmonary outcomes and adverse effects were evaluated. All data were analysed using RevMan 5.1. Meta‐analyses were performed using relative risk (RR), risk difference (RD), and mean difference (MD) with their 95% confidence intervals (CI). If RD was significant, the numbers needed to benefit (NNTB) or to harm (NNTH) were calculated. No new trials were identified in this update. Two trials qualified for inclusion in this review. The incidence of CLD at 36 weeks PMA was increased (of borderline statistical significance) in the inhaled steroid group [RR 1.45 (95% CI 0.99 to 2.11); RD 0.11 (95% CI 0.00 to 0.21), p = 0.05, one trial, n = 278]. The incidence of CLD at 36 weeks PMA among all survivors [RR 1.34 (95% CI 0.94 to 1.90); RD 0.11 (95% CI ‐0.02 to 0.24), one trial, n = 206], oxygen dependency at 28 days (two trials, n = 294), death by 28 days (two trials, n = 294) or 36 weeks PMA (two trials, n = 294) and the combined outcome of death or CLD by 28 days (two trials, n = 294) or 36 weeks PMA (one trial, n = 278) did not differ significantly between the groups. The duration of mechanical ventilation was significantly longer in the inhaled steroid group as compared to the systemic steroid group [typical MD 4 days (95% CI 0.2 to 8); two trials, n = 294] as was the duration of supplemental oxygen [typical MD 11 days (95% CI 2 to 20); two trials, n = 294]. The incidence of hyperglycaemia was significantly lower in the group receiving inhaled steroids [RR 0.52 (95% CI 0.39 to 0.71); RD ‐0.25 (95% CI ‐0.37 to ‐0.14); one trial, n = 278; NNTB 4 (95% CI 3 to 7) to avoid one infant experiencing hyperglycaemia]. The rate of patent ductus arteriosus was increased in the group receiving inhaled steroids [RR 1.64 (95% CI 1.23 to 2.17); RD 0.21 (95% CI 0.10 to 0.33); one trial, n = 278; NNTH 5 (95% CI 3 to 10)]. No information was available on long‐term neurodevelopmental outcomes. This review found no evidence that early inhaled steroids confer important advantages over systemic steroids in the management of ventilator dependent preterm infants. Neither inhaled steroids nor systemic steroids can be recommended as a part of standard practice for ventilated preterm infants. Because they might have fewer adverse effects than systemic steroids, further randomised controlled trials of inhaled steroids are needed that address risk/benefit ratio of different delivery techniques, dosing schedules and long‐term effects, with particular attention to neurodevelopmental outcome. 插管之極低出生體重早產兒使用吸入性跟全身性類固醇預防慢性肺疾病之比較 儘管產前類固醇使用、表面張力素替代治療及其他新生兒加護治療的進步,慢性肺疾病仍舊是早產兒死亡及罹病的主要原因。細胞及生物化學研究逐漸顯示發炎反應在慢性肺疾病的病生理扮演著重要角色,減少或調整發炎反應的治療可能可以減少慢性肺疾病的發生率或嚴重度。學理上來說,使用吸入性類固醇可能可以對肺部系統有益,同時沒有全身性的高濃度及較少副作用的危險。 比較插管之極低出生體重嬰兒,出生前兩週內使用吸入性及全身性類固醇預防慢性肺疾病的效果。 搜尋以下資料庫:Cochrane Controlled Trials Register (The Cochrane Library, Issue 2, 2007) 、MEDLINE (1966  June 2007) 、EMBASE (1980  June 2007) 、CINAHL (1982  June 2007) ,以及發表試驗的參考資料、發表在Pediatric Research的摘要或the Pediatric Academic Societies website (1990  April 2007) 的電子刊物。 所有隨機及近似隨機的臨床試驗,有關極低體重早產兒接受呼吸器治療,在出生後前兩週使用吸入性及全身性類固醇治療之比較 (不論劑量及治療時間) 。 分析的臨床結果資料包括28天大 (或懷孕週數36週) 的慢性肺疾病、死亡率、合併結果、其他肺部後果及不良反應,全部資料均用RevMan 4.2分析;合適的資料會進一步統合分析,計算relative risk (RR) 、risk difference (RD) 、及含95% confidence intervals (CI) 的weighted mean difference (WMD) ,如果RD有顯著意義,會再去計算the number needed to treat (NNT) 或the number needed to harm (NNH) 。 本次更新文獻有找到額外兩個評估全身性及吸入性類固醇的試驗,但這兩個試驗因為新生兒在隨機接受吸入性類固醇之前已接受過全身性類固醇或安慰劑故必須被排除。兩個試驗合格列入本次回顧,吸入性類固醇族群在懷孕週數36週大的慢性肺疾病機率有增加,近乎統計學上顯著意義[RR 1.45 (95% CI 0.99, 2.11); RD 0.11 (95% CI 0.00, 0.21), p = 0.05,一個試驗278個個案]。所有存活嬰兒在懷孕週數36週時慢性肺疾病的發生率無統計上差異[RR 1.34 (95% CI 0.94, 1.90); RD 0.11 (95% CI −0.02, 0.24) ,一個試驗206個個案],28天大時的氧氣依賴 (兩個試驗,個案數294人) 、28天大或懷孕週數36週前死亡 (兩個試驗,個案數294人) 、28天大死亡或慢性肺疾病 (兩個試驗,個案數294人) 或36週大死亡或慢性肺疾病 (一個試驗,個案數278人) 並無統計上差異。呼吸器的使用期間在吸入性類固醇族群顯著較久 (typical WMD 4天, 95% CI 0.2, 8;兩個試驗,294個個案) ,氧氣使用期間也明顯較久 (typical WMD 11天, 95% CI 2, 20;兩個試驗,294個個案) ,高血糖的發生率在吸入性類固醇族群則顯著較低 (RR 0.52, 95% CI 0.39, 0.71; RD −0.25, 95% CI −0.37, −0.14;一個試驗,278個個案) ,避免嬰兒發生高血糖的NNT是4 (95% CI 3, 7) 。接受吸入性類固醇族群的開放性動脈導管機率明顯增加 (RR 1.64, 95% CI 1.23, 2.17; RD 0.21, 95% CI 0.10, 0.33;一個試驗,278個個案) ,NNH是5 (95% CI 3) ;吸入性類固醇族群腸胃道出血及穿孔機率的降低有近似統計上的意義:腸胃道出血[RR 0.40, 95% CI 0.16, 1.02; RD −0.06, 95% CI −0.12, 0.00, p = 0.05 (一個試驗,278個個案)]、腸胃道穿孔[RR 0.16, 95% CI 0.02, 1.29; RD −0.04, 95% CI −0.07, 0.00, p = 0.05 (一個試驗,278個個案)]。其他不良反應在兩個族群無統計上差異,也沒有長期神經學發展結果的資料。 在使用呼吸器早產兒早期使用吸入性類固醇跟全身性類固醇相比,本次回顧並未發現更多好處,不管吸入性或全身性類固醇使用都不被建議當作常規使用。吸入性類固醇可能有較少副作用,針對不同給藥方式的風險跟好處、劑量時程及長期效果,特別是神經發展結果,需要進一步的隨機試驗。 本摘要由馬偕醫院林千裕翻譯。 此翻譯計畫由臺灣國家衛生研究院 (National Health Research Institutes, Taiwan) 統籌。 需要呼吸支持的早產兒常合併慢性肺疾病,肺部發炎反應被認為是病因之一,類固醇可口服或靜脈給予來減少發炎反應,然而使用類固醇合併有嚴重副作用,比如腦性麻痺 (運動問題) 及發展遲緩;吸入性類固醇可能直接作用到肺部減少這些副作用。本次回顧針對需要呼吸支持的早產兒使用吸入性類固醇跟全身性類固醇 (口服或靜脈) 之比較,無證據支持吸入性類固醇可預防慢性肺疾病或減少呼吸支持及氧氣給予的天數。 Corticostéroïdes inhalés versus systémiques pour la prévention des maladies pulmonaires chroniques chez les nouveau-nés prématurés de très faible poids de naissance ventilés Les maladies pulmonaires chroniques (MPC) demeurent une cause importante de mortalité et de morbidité chez les nourrissons prématurés et l'inflammation joue un rôle important dans leur pathogenèse. L'utilisation de corticostéroïdes inhalés peut moduler le processus inflammatoire sans les concentrations élevées concomitantes en stéroïdes systémiques et avec moins de risques d'effets indésirables. Déterminer l'effet des corticostéroïdes inhalés versus systémiques démarrés au cours des deux premières semaines de vie sur la prévention des MPC chez les nourrissons de très faible poids de naissance (TFPN) ventilés. Des essais randomisés et quasi‐randomisés ont été identifiés en effectuant des recherches dans The Cochrane Library, MEDLINE , EMBASE , CINAHL, les bibliographies d'essais publiés et les résumés publiés dans Pediatric Research ou par des recherches électroniques sur le site web des Sociétés pédiatriques (Pediatric Academic Societies) en juin 2007. Ces recherches ont été mises à jour en juin 2011 et ont inclus des recherches supplémentaires dans Clinicaltrials.gov, Controlled‐trials.com et Web of Science. Les essais cliniques randomisés ou quasi‐randomisés comparant un traitement aux corticostéroïdes inhalés versus systémiques (indépendamment de la dose et de la durée du traitement) démarré au cours des deux premières semaines de vie chez des nouveau‐nés TFPN recevant une ventilation assistée. Les critères de jugement comprenant les MPC à 28 jours ou 36 semaines d'âge post‐menstruel (APM), les critères de jugement combinés relatifs aux décès ou aux MPC à 28 jours ou 36 semaines en APM, les autres critères de jugement pulmonaires et les effets indésirables, ont été évalués. Toutes les données ont été analysées au moyen de RevMan 5.1. Des méta‐analyses ont été réalisées en utilisant le risque relatif (RR), la différence de risques (DR) et la différence moyenne (DM) avec leur intervalle de confiance (IC) à 95 %. Si la DR était significative, le nombre de sujets à traiter pour observer un bénéfice (NST) ou le nombre nécessaire pour nuire (NNN) étaient calculés. Aucun nouvel essai n'a été identifié dans cette mise à jour. Deux essais ont été inclus dans cette revue. L'incidence des MPC à 36 semaines en APM a augmenté (signification statistique limite) dans le groupe des stéroïdes inhalés [RR 1,45 (IC à 95 % 0,99 à 2,11) ; DR 0,11 (IC à 95 % 0,00 à 0,21), p = 0,05, un essai, n = 278]. L'incidence des MPC à 36 semaines en APM parmi tous les survivants [RR 1,34 (IC à 95 % 0,94 à 1,90) ; DR 0,11 (IC à 95 % ‐0,02 à 0,24), un essai, n = 206], de la dépendance à l'oxygène à 28 jours (deux essais, n = 294), des décès à 28 jours (deux essais, n = 294) ou à 36 semaines en APM (deux essais, n = 294) et du critère de jugement combiné relatif aux décès ou aux MPC à 28 jours (deux essais, n = 294) ou 36 semaines en APM (un essai, n = 278) n'a pas connu de différence significative entre les groupes. La durée de la ventilation mécanique a été significativement plus longue dans le groupe des stéroïdes inhalés comparé au groupe des stéroïdes systémiques [DM type 4 jours (IC à 95 % 0,2 à 8) ; deux essais, n = 294], de même que la durée de la supplémentation en oxygène [DM type 11 jours (IC à 95 % 2 à 20) ; deux essais, n = 294]. L'incidence de l'hyperglycémie était significativement plus faible dans le groupe recevant des stéroïdes inhalés [RR 0,52 (IC à 95 % 0,39 à 0,71) ; DR ‐0,25 (IC à 95 % ‐0,37 à ‐0,14) ; un essai, n = 278 ; NST 4 (IC à 95 % 3 à 7) pour éviter qu'un nourrisson souffre d'hyperglycémie]. Le taux de persistance du canal artériel a augmenté dans le groupe recevant des stéroïdes inhalés [RR 1,64 (IC à 95 % 1,23 à 2,17) ; DR 0,21 (IC à 95 % 0,10 à 0,33) ; un essai, n = 278 ; NNN 5 (IC à 95 % 3 à 10)]. Aucune information n'était disponible sur les critères de jugement relatifs au développement neurologique à long terme. Cette revue n'a trouvé aucune preuve indiquant que les stéroïdes inhalés précocement conféraient des avantages importants par rapport aux stéroïdes systémiques dans la gestion des nourrissons prématurés sous assistance ventilatoire. Ni les stéroïdes inhalés ni les stéroïdes systémiques ne peuvent être recommandés dans le cadre d'une pratique standard pour les nourrissons prématurés ventilés. Du fait qu'ils pourraient avoir moins d'effets indésirables que les stéroïdes systémiques, il est nécessaire de réaliser des essais contrôlés randomisés supplémentaires sur les stéroïdes inhalés en examinant le rapport risque/bénéfice de différentes techniques d'administration, les différents schémas posologiques et les effets à long terme en prêtant une attention particulière au développement neurologique. 人工呼吸器管理を受けた極低出生体重早産児での慢性肺疾患予防を目的とした吸入副腎皮質ステロイド(薬)(以下、ステロイド)と全身ステロイドとの比較 慢性肺疾患(CLD)は、依然として早産児の死亡と罹病の重要な原因の一つであり、その病理発生において炎症が重要な役割を担っている。吸入ステロイドの使用により、全身へのステロイド濃度が同時に高くなることなく炎症過程を変化させ、有害作用リスクが少なくなる可能性がある。 人工呼吸器管理を受けた極低出生体重(VLBW)児でのCLD予防に対する、生後2週以内に開始された吸入ステロイドの効果を全身ステロイドと比較し検討すること。 コクラン・ライブラリ、MEDLINE、EMBASE、CINAHL、発表された研究の文献リスト、Pediatric ResearchまたはPediatric Academic Societies web site電子版での発表抄録を2007年6月に検索し、ランダム化試験および準ランダム化試験を同定した。本検索を2011年6月に更新し、Clinicaltrials.gov、Controlled‐trials.com、Web of Scienceに対するその後追加された検索を含めた。 補助呼吸を受けているVLBW児を対象に生後2週以内に開始した、吸入ステロイドを全身ステロイド療法(用量と治療期間を問わず)と比較しているランダム化臨床試験または準ランダム化臨床試験 生後28日目または妊娠週数(PMA)36週時のCLD、死亡率、生後28日目またはPMA36週時の死亡またはCLDという複合アウトカム、他の呼吸系アウトカム、有害作用などのアウトカムを評価した。RevMan 5.1を用いてすべてのデータを解析した。相対リスク(RR)、リスク差(RD)、平均差(MD)およびその95%信頼区間(CI)を用いてメタアナリシスを実施した。RDが有意の場合、利益に対する治療必要数(NNTB)または害に対する治療必要数(NNTH)を算出した。 本更新で新たな試験は同定されなかった。本レビューにおいて2件の試験が選択基準を満たした。PMA36週時のCLD罹患率は、吸入ステロイド群で上昇した(統計学的有意性はボーダーラインである)[RR 1.45 (95%CI 0.99~2.11)、RD 0.11 (95%CI 0.00~0.21)、p = 0.05、1試験、278名]。全生存者でのPMA36週時のCLD罹患率[RR 1.34 (95%CI 0.94~1.90)、RD 0.11 (95%CI ‐0.02~0.24)、1試験、206名]、生後28日目の酸素依存性(2試験、294名)、生後28日目までの死亡(2試験、294名)、生後28日目までの死亡とCLDの複合アウトカム(2試験、294名)、PMA36週時までの死亡とCLDの複合アウトカム(1試験、278名)に群間で有意差はなかった。機械的換気期間は、全身ステロイド群に比べて吸入ステロイド群の方が有意に長く[定型的MD 4日(95%CI 0.2~8)、2試験、294名]、酸素補充期間も同様であった[定型的MD 11日(95%CI 2~20)、2試験、294名]。 高血糖罹患率は、吸入ステロイド群の方が有意に低かった[RR 0.52 (95%CI 0.39~0.71)、RD ‐0.25 (95%CI ‐0.37~‐0.14)、1試験、278名;1名の児の高血糖発症を回避するNNTB 4 (95%CI 3~7)]。動脈管開存症の率は吸入ステロイド群で上昇した[RR 1.64 (95%CI 1.23~2.17)、RD 0.21 (95% CI 0.10~0.33)、1試験、278名;NNTH 5 (95%CI 3~10)]。長期の神経発達アウトカムに関する情報は得られなかった。 呼吸器を必要とする早産児の管理において、早期吸入ステロイドの方が全身ステロイドに比べて重大な利益をもたらすというエビデンスを本レビューでは認めなかった。吸入ステロイドと全身ステロイドのいずれも、人工呼吸器管理の早産児に対する標準診療の一部として推奨できない。吸入ステロイドは全身ステロイドより有害作用が少ない可能性があるため、様々な投与法、投与スケジュール、特に神経発達アウトカムに注目した長期的効果のリスク/利益比に取り組むような、吸入ステロイドについてのさらなるRCTが必要である。


  • Perinatal dengue infection: Two new cases

    by S.S. Shah, P. Bhide, P. Mankare

    Dengue infection is commonly observed in tropical countries, but its transmission from mother to baby has not been frequently described. We report two cases with neonatal dengue infection due to perinatal transmission. The first signs of dengue appeared on day 4 of life in both the infants. Initially a bacterial infection was suspected. Clinical diagnosis of dengue fever was confirmed by appropriate laboratory testing. In areas where dengue is endemic, the diagnosis of dengue should be considered in a neonate with signs of sepsis. When dengue is suspected in a parturient woman, laboratory investigation and extended observation of the newborn are advised.